PTC Therapeutics, Inc.
PTCT
$46.41
-$0.53-1.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 8.33% | 5.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.33% | 5.40% | |||
| Cost of Revenue | -18.12% | 16.63% | |||
| Gross Profit | 194.05% | -37.13% | |||
| SG&A Expenses | 15.28% | 5.69% | |||
| Depreciation & Amortization | 8.93% | 5.97% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.92% | 13.04% | |||
| Operating Income | 69.46% | -55.79% | |||
| Income Before Tax | 3.36% | -14.30% | |||
| Income Tax Expenses | -432.60% | -35.57% | |||
| Earnings from Continuing Operations | 38.22% | -7.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.22% | -7.54% | |||
| EBIT | 69.46% | -55.79% | |||
| EBITDA | 79.98% | -72.67% | |||
| EPS Basic | 38.45% | -7.26% | |||
| Normalized Basic EPS | 143.69% | -33.28% | |||
| EPS Diluted | 38.45% | -7.26% | |||
| Normalized Diluted EPS | 143.69% | -33.28% | |||
| Average Basic Shares Outstanding | 0.36% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||